Clinically, previous studies have revealed that SETD8 is highly expressed in several types of cancers and an decrease in SETD8 expression is associated with a better survival rate, implying SETD8 as a potential therapeutic target in human disease interventions [1, 4, 5, 20, 37, 82, 89, 95–97]. Here, KMT5A is linked to cancer.